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Symptoms of depression and anxiety predict
treatment response and long-term physical health
outcomes in rheumatoid arthritis: secondary analysis
of a randomized controlled trial
Faith Matcham1, Sam Norton2, David L. Scott3, Sophia Steer3
and Matthew Hotopf1
Abstract
Objective. The aim of this analysis is to examine the longitudinal impact of symptoms of depression/
anxiety on treatment response, long-term disease activity and physical disability in RA.
Methods. Secondary analysis of clinical trial data was performed. Data were collected at baseline and at
6-monthly intervals for 2 years. The EuroQoL (EQ-5DTM) indicated depression/anxiety symptom severity.
Our primary outcomes of interest were (i) DAS-28 and (ii) physical disability measured via the HAQ.
Secondary outcomes were: tender and swollen joint counts, patient global assessment, ESR and odds
of reaching clinical remission. Multilevel models were used to assess the impact of baseline and persistent
depression/anxiety on outcomes over 2 years.
Results. Data from 379 patients were included. After adjusting for covariates, baseline depression/anxiety
symptoms were associated with increased DAS-28 outcomes and increased tender joint counts. Persistent
depression/anxiety symptoms were associated with increased DAS-28 scores, HAQ scores, tender joint
counts and patient global assessment of disease activity, and reduced odds of reaching clinical remission.
Patients with symptoms of depression/anxiety at baseline also showed a 50% reduction in prednisolone
treatment effect, in comparison with patients with no symptoms of depression/anxiety at baseline.
Conclusion. Baseline and persistent symptoms of depression/anxiety are associated with poorer health
outcomes over time, as well as reduced treatment response. Mental health should be routinely measured
both in clinical practice and in research, and managed alongside rheumatological disease to optimize
health outcomes. Further research is required to examine whether treatment of mental disorders can
improve rheumatological outcomes.
Key words: depression, anxiety, rheumatoid arthritis (RA), longitudinal, disease activity, HAQ, pain, joint ero-
sion, remission.
Rheumatology key messages
. Depression/anxiety symptoms are associated with increased long-term RA disease activity and physical disability.
. Persistent depression/anxiety is associated with reduced odds of reaching RA remission at 2 years.
. Baseline depression/anxiety is associated with 50% reduction in prednisolone treatment response in RA.
Introduction
Depression and anxiety are highly prevalent in RA, with a
recent meta-analysis reporting a 16.8% point prevalence
of depression, diagnosed via clinical interview [1]. This
represents a substantially higher level of depression than
that found in the general population, where estimates are
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typically 5.0% [2]. Additionally, 25.1% of RA outpatients
screen positive for anxiety, according to the 7-item
Generalized Anxiety Disorder (GAD-7 [3]) questionnaire
[4], and 16.3% of RA patients screen positive for both
anxiety and depression [4]. Not only are prevalence
levels of depression and anxiety high, but an analysis of
the Early Rheumatoid Arthritis Network sample found that
12% of RA patients report persistently high levels of dis-
tress throughout the first 10 years after diagnosis [5].
Depression and anxiety in RA have been shown to be
associated with increased pain [6] and fatigue [7], reduced
quality of life [8], and increased service use [9], disease ac-
tivity [10] and disability [11]. Depression in RA can also in-
crease the risk of premature mortality [12]. The mechanism
for the association between mood and disease outcomes is
uncertain and probably bidirectional [13]. There are several
pathways through which psychological distress may impact
health outcomes: distress can interfere with the stress re-
sponse and produce glucocorticoid resistance [1417].
Additionally, depression/anxiety in RA may also reduce ad-
herence to medication [18] and inflate the reported severity
of subjective symptoms such as pain, joint tenderness and
physical dysfunction [19]. Furthermore, depression/anxiety
also impact on physical behaviour and may result in reduced
movement, a deconditioning of the body, loss of natural
endorphins and increasing levels of pain [20].
There is systematic review evidence to suggest a down-
stream relationship between distress and disease out-
comes, with depression increasing pain and disease
activity, and decreasing short- and long-term treatment
efficacy [21]. However the authors noted that the quality
of the included research studies was low, with poor sam-
pling and recruitment strategies, small sample sizes, inad-
equate adjustment for confounders and lack of
information regarding randomization, measurement blind-
ing and attrition rates. More research is needed to resolve
these issues, which are of considerable clinical relevance
because pharmacologic and psychological treatments
could be used more widely to treat depression in RA if it
is a substantial driver of disease activity.
This study aims to fill these gaps in the evidence by
undertaking a secondary analysis of an existing rando-
mized controlled trial in patients with early RA. We as-
sessed three interrelated hypotheses: more symptoms
of depression and anxiety at baseline status will predict
increased DAS-28 and HAQ outcomes over a 2-year
follow-up period; patients with persistent symptoms of
depression and anxiety will show increased DAS-28 and
HAQ outcomes over a 2-year follow-up period than will
patients without such symptoms; and depression and
anxiety symptoms at baseline will be associated with re-
stricted treatment response to glucocorticoid treatment,
measured via the HAQ and the DAS-28.
Patients and methods
Study design
This study comprised a secondary analysis of data col-
lected as part of a factorial randomized controlled trial of
glucocorticoids and combination DMARDs in patients
with early RA: Combination Anti-Rheumatic Drugs in
Early Rheumatoid Arthritis (CARDERA) [22]. This paper re-
ports findings from a secondary data analysis only, and
required no additional ethical approval.
Participants
Participants in the trial were 467 consecutively recruited
patients from rheumatology outpatient clinics across 42
centres in England and Wales. The inclusion criteria for
enrolment were: ability to give informed consent; aged
over 18 years; and active RA (determined by the ACR
criteria) for <2 years, with three of the following:53 swol-
len joints;56 tender joints; morning stiffness for545 min;
ESR of 528 mm/h. Patients were excluded according to
the following criteria: other inflammatory arthropathies;
current use of oral glucocorticoids; serious physical
comorbidities; women with the possibility of pregnancy;
contraindications for drug trials.
Interventions
Detailed summaries of the intervention content are pro-
vided in the original trial article [22]. In short, patients
were randomly allocated to receive one of four treatment
options: (i) MTX (commencing 7.5 mg weekly, increasing
incrementally to 15 mg/week target dose); (ii) MTX and
ciclosporin (started 3 months after MTX, commencing
100 mg/day, increasing incrementally to 3 mg/kg daily
target dose); (iii) MTX and prednisolone (started alongside
MTX, commencing 60 mg/day, reduced to 7.5 mg at
6 weeks, 7.5 mg daily between 6 and 28 weeks, and
stopped by 34 weeks); and (iv) MTX and ciclosporin and
prednisolone. Of the 467 randomized patients, 88 were
lost to follow-up and 132 discontinued the intervention,
spread relatively evenly across treatment groups.
The primary outcome of the original trial was the devel-
opment of new erosions in X-rays of hands and feet; how-
ever, several secondary outcomes were also collected at
baseline and at 6-monthly intervals for the duration of the
2-year trial. Secondary outcomes in the original trial
included function, quality-of-life, disease activity and ad-
verse events.
Symptoms of depression/anxiety
Rheumatology trials do not measure mood systematically
using diagnostic interviews, or typically even with vali-
dated symptom severity scales such as the Patient
Health Questionnaire (PHQ)-9 [23]. We therefore relied
upon patients’ responses to the depression/anxiety item
of the EuroQoL (EQ-5DTM; [24]). The EQ-5DTM asks pa-
tients to respond to five health domains (mobility, self-
care, usual activities, pain/discomfort and anxiety/depres-
sion) according to how they are feeling today. The depres-
sion/anxiety domain provides three answer options: I am
not anxious or depressed; I am moderately anxious or
depressed; or I am extremely anxious or depressed.
Patients’ responses to this domain of the EQ-5DTM at
baseline were used to categorize patients into one of
three baseline mood categories: no depression/anxiety;
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moderate depression/anxiety; extreme depression/anx-
iety. Although not a validated method of identifying
mood disorders, there is evidence to suggest good sen-
sitivity of similar one-item measures. Meta-analysis evi-
dence from the National Institute for Health and Care
Excellence (NICE) suggests that one-item mood screening
questionnaires have 84% sensitivity and 65% specificity
[25]. We can be fairly certain that we have identified pa-
tients with depression/anxiety; however, there may also
be patients with subthreshold psychological distress
included in our groups. Therefore, rather than indicating
the presence of a diagnosed mood disorder, we have
used responses to this tool to quantify levels of general
psychological distress in participants that, for the pur-
poses of this study, we refer to as depression/anxiety
symptoms.
The persistence of depression/anxiety symptoms
throughout the course of the trial was also established
using the responses to the EQ-5DTM. To examine the
impact of persistent depression/anxiety symptoms on
physical health outcomes, patients were categorized into
four mutually exclusive groups, according to their EQ-
5DTM scores across all measurement time points: never
reporting depression/anxiety symptoms; reporting de-
pression/anxiety symptoms <50% of the time; reporting
depression/anxiety symptoms >50% of the time; report-
ing depression/anxiety symptoms at every time point.
Outcomes
Our primary outcomes are DAS-28 and HAQ [26]. The
DAS-28 is the gold standard for measuring RA disease
activity: it is recommended by all major RA guidelines; it
is easily calculated, and widely accepted as a high-quality
indicator of the value of treatment [27]. The HAQ [26] is a
self-reported measure, recommended by clinical guide-
lines to measure functional ability [27]. Both the DAS-28
and HAQ are used widely, both as outcomes in clinical
trials and in clinical practice, and were therefore selected
as primary outcomes for the current analysis [27, 28].
Secondary outcomes of interest are the components of
the DAS-28: tender joint count (TJC), swollen joint count
(SJC), ESR and patient global assessment (PGA). We also
examined the relationship between depression/anxiety
symptoms and the odds of reaching clinical remission at
the study end point. This was assessed through establish-
ing the number of patients scoring <2.6 on the DAS-28 at
2-year follow-up [29]. These were included in the current
analysis as secondary outcomes, and were all measured
at 6-, 12-, 18- and 24-months following baseline
assessment.
Data analysis
Multilevel models were used to examine hypotheses 1 and
2, pooling across the CARDERA 2-year treatment arms.
Multilevel modelling is designed to handle hierarchically
nested data, allowing for missing outcome data, and ac-
counting for variation both between participants and
within patients over time. These models were estimated
using Stata (version 11.0), which provides parameters in
the form of unstandardized maximum likelihood estimates
(b coefficients), which estimate magnitude and direction
of changes in outcome variables associated with differ-
ences in predictor variables (in this case, depression/anx-
iety). All models included random intercepts to account for
variation in the outcome variable across individuals.
Assessment time was included as a dummy coded vari-
able, with a random time slope to allow for variation in
change in the outcome over time across individuals.
Alongside the b coefficients, confidence intervals and
P-values, we also calculated standardized mean differ-
ence effect sizes, to provide an estimate of the standar-
dized effect size of depression/anxiety status on physical
health outcomes.
Multilevel linear models for hypotheses 1 and 2 were
created in two stages for continuous outcome variables
at the post-intervention assessments. First, unadjusted
models including only depression/anxiety status and
time were estimated; second, adjusted models were esti-
mated that additionally included age, gender, disease dur-
ation, time, baseline level of physical health, the type of
treatment received and RF status. Additionally, in models
of DAS-28 outcomes, HAQ scores were adjusted for; in
models of HAQ outcomes, DAS-28 scores were adjusted
for. Additional logistic regression models, adjusting for the
same variables, were created to assess whether baseline
depression/anxiety and persistent depression/anxiety
predicted clinical remission at 2 years.
To assess hypothesis 3, a multiple regression model
was created, examining the interaction between baseline
depression/anxiety status and the receipt of steroidal
treatment on physical health outcomes over the initial
6 months of treatment. Follow-up responses were limited
to the first 6 months of treatment due to the step-down
treatment regime utilized [22] and in order to examine the
short-term treatment response that is appropriate for this
medication type. The regression model for hypothesis 3
was adjusted for age, gender, disease duration, baseline
physical health and RF status.
Results
Participant characteristics
Of the original 467 participants randomized in the
CARDERA trial, 379 (81.2%) completed the trial and
were included in this secondary analysis. Table 1 shows
the baseline demographic, clinical and psychological vari-
ables for participants.
The relationship between baseline depression/anxiety
and health outcomes
Primary outcomes analysis
Fig. 1 shows the changes in observed DAS-28 and HAQ
scores over time. These results are also summarized in
Table 2. Before adjusting for covariates, in comparison
with patients with no symptoms of depression/anxiety at
baseline, patients with moderate depression/anxiety re-
ported significantly increased scores over time. Patients
with extreme baseline depression/anxiety also reported
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significantly increased HAQ scores over time. After adjust-
ing for age, gender, disease duration, time, treatment
type, baseline HAQ and DAS-28 scores, RF status and
disease activity, there were no longer between-group
differences in HAQ outcomes over time (Table 2). After
adjusting for age, gender, disease duration, time, treat-
ment type, baseline level of disease activity and HAQ
scores, patients with extreme baseline depression/anxiety
TABLE 1 Baseline demographic, clinical and psychological variables
Variable
Total
sample,
n=379
No baseline
depression/
anxiety, n=166
Moderate
baseline
depression/anxiety,
n=180
Extreme
baseline
depression/
anxiety, n=24
Age, mean (S.D.) 54.1 (12.3) 54.1 (12.3) 54.7 (12.4) 49.1 (10.5)
Female,a % 68.3 62.7 70.6 83.3*
Disease duration, mean (S.D.),b months 3.9 (5.4) 3.8 (5.2) 4.1 (5.5) 1.5 (1.9)*
Ethnicity,c n (%)
AfroCaribbean 6 (1.6) 1 (0.6) 4 (2.2)* 1 (4.2)
Asian 6 (1.6) 1 (0.6) 3 (1.7) 2 (8.3)
White-British 364 (96.0) 164 (98.8) 172 (95.6) 20 (83.3)
White-European 2 (0.5) 0 (0.0) 0 (0.0) 1 (4.2)
Other 1 (0.3) 0 (0.0) 1 (0.6) 0 (0.0)
RF positive, n (%) 254 (67.0) 114 (68.7) 117 (65.0) 18 (75.0)
Larsen score, median (IQR) 7.0 (3.017.0) 7.0 (2.517.0) 7.0 (3.016.0) 6.5 (1.517.5)
DAS28, mean (S.D.)d 5.7 (1.3) 5.3 (1.3) 6.0 (1.1)*** 6.5 (1.3)***
HAQ, mean (S.D.)e 1.6 (0.7) 1.3 (0.7) 1.7 (0.6)*** 2.0 (0.6)***
TJC, mean (S.D.)f 11.4 (7.6) 9.9 (7.2) 12.2 (7.5)** 15.5 (8.6)**
SJC, mean (S.D.)g 9.7 (6.2) 8.4 (5.6) 10.8 (6.4)*** 11.7 (7.4)*
ESR, mean (S.D.) 41.4 (29.5) 38.4 (28.7) 44.5 (30.3) 40.3 (28.7)
PGA, mean (S.D.)h 55.2 (26.3) 45.8 (25.4) 60.3 (24.6)*** 77.3 (22.5)***
aExtreme baseline depression/anxiety has a significantly higher percentage female than no baseline depression/anxiety.
bExtreme baseline depression/anxiety has a significantly shorter disease duration than no baseline depression/anxiety.
cModerate baseline depression/anxiety has significantly more AfroCaribbean patients than no baseline depression/anxiety.
dModerate and extreme baseline depression/anxiety has a significantly higher baseline DAS28 than no baseline depression/
anxiety. eModerate and extreme baseline depression/anxiety has a significantly higher baseline HAQ than no baseline de-
pression/anxiety. fModerate and extreme baseline depression/anxiety has a significantly higher baseline TJC than no baseline
depression/anxiety. gModerate and extreme baseline depression/anxiety has a significantly higher baseline SJC than no
baseline depression/anxiety. hModerate and extreme baseline depression/anxiety has a significantly higher baseline PGA
than no baseline depression/anxiety. *Significant between-group difference P< 0.05. **Significant between-group difference
P< 0.01. ***Significant between-group difference P< 0.001. SF-36: Short-Form 36-item health survey.
FIG. 1 Estimated unadjusted mean outcomes by baseline depression/anxiety (with standard error bars) for DAS-28/ HAQ
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showed significantly increased levels of follow-up DAS-28
in comparison with patients with no depression/anxiety at
baseline.
Secondary outcomes analysis
In comparison with patients with no depression/anxiety at
baseline, patients with moderate depression/anxiety at
baseline reported significantly increased PGA, and patients
with extreme depression/anxiety reported significantly
increased PGA and TJC (Table 2). The relationship between
baseline depression/anxiety and long-term TJC outcomes
was sustained after adjusting for all covariates. The rela-
tionships between depression/anxiety and SJC and ESR
outcomes did not reach statistical significance, and effect
sizes were small.
At 2-year follow-up, 80 (21.1%) patients reached clinical
remission, achieving DAS-28 scores of <2.6. Patients re-
porting moderate depression/anxiety had reduced odds
of reaching clinical remission in comparison with patients
with no depression/anxiety at baseline (OR = 0.50, stand-
ard error [S.E.] = 0.14, P= 0.02, 95% CI: 0.29, 0.88).
Patients with extreme depression/anxiety symptoms at
baseline had reduced odds of reaching clinical remission
at 2-year follow-up in comparison with patients with no
depression/anxiety symptoms at baseline; however, this
comparison was non-significant (OR = 0.77, S.E. = 0.43,
P= 0.64, 95% CI: 0.25, 2.33). This may be due to the
small number of patients with extreme symptoms at base-
line (n= 24), reducing the power to find a significant effect
and resulting in an imprecise estimate.
The relationship between persistent depression/
anxiety and health outcomes
Primary outcomes analysis
Fig. 2 shows the changes in observed DAS-28 and HAQ
scores over time according to the persistence of depres-
sion/anxiety symptoms. Before adjusting for covariates,
increasing persistence of depression/anxiety symptoms
was associated with increased HAQ and DAS-28 severity
over time (Table 3). These significant relationships were
sustained after adjusting for age, gender, disease dur-
ation, time, baseline physical health, treatment type, RF
status and HAQ/DAS-28. In comparison with patients who
were never depressed/anxious, patients with depression/
anxiety symptoms <50% of the, >50% of the time, or at
all time points reported significantly increased HAQ
scores at follow-up. In comparison with patients who
were never depressed/anxious, patients with depres-
sion/anxiety symptoms <50% of the time, >50% of the
time or at all time points reported significantly increased
DAS-28 scores at follow-up.
Secondary outcomes analysis
After adjusting for covariates, in comparison with patients
who were never depressed/anxious, patients depressed/
anxious <50% of the time, >50% of the time or at all time
points reported significantly increased TJC at follow-up. In
comparison with patients who were never depressed/anx-
ious, patients depressed/anxious <50% of the, >50% of
the time or at all time points reported significantly
increased PGA at follow-up. ESR scores were not asso-
ciated with depression/anxiety persistence, and the rela-
tionship between persistent depression/anxiety and SJC
outcomes showed moderate effect sizes, although did not
reach statistical significance (Table 3).
Logistic regression analyses revealed that after control-
ling for all clinical and demographic variables, in compari-
son with patients never reporting depression/anxiety,
patients reported symptoms of depression/anxiety at
<50% of the time points did not have significantly smaller
odds of reaching clinical remission (OR = 0.58, S.E. = 0.19,
P= 0.09). However, both patients reporting symptoms of
depression/anxiety at >50% of the time points (OR = 0.38,
S.E. = 0.17, P< 0.05) and patients reporting depression/
anxiety at every time point (OR = 0.10, S.E. = 0.08,
P< 0.01) showed significantly smaller odds of reaching
clinical remission when compared with patients with no
symptoms of depression throughout. Adjustment for
baseline depression status in these models did not signifi-
cantly alter our findings (data not shown).
FIG. 2 Estimated unadjusted mean outcomes by depression/anxiety persistence (with standard error bars) for DAS-28/
HAQ
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Symptoms of depression/anxiety and anxiety
at baseline are associated with reduced
response to prednisolone
Regression models adjusted for age, gender, disease dur-
ation, baseline HAQ for DAS outcomes and baseline DAS
for HAQ outcomes, RF status and DAS-28/HAQ were cre-
ated to assess the interaction between baseline depres-
sion/anxiety and treatment type on change in HAQ and
DAS-28 outcomes for the first 6 months of treatment.
A significant interaction between mood status at base-
line and receipt of prednisolone was found for HAQ out-
comes: in comparison with patients with no low mood at
baseline, patients with moderate symptoms of depres-
sion/anxiety taking prednisolone reported significantly
higher follow-up HAQ scores (b coefficient = 0.25,
S.E. = 0.12, standardized mean differences = 0.14,
P= 0.05). The effect of steroidal treatment on HAQ out-
comes was 0.48 for patients without depression/anxiety;
however, this decreased to 0.23 for patients with some
depression/anxiety. This represents a 48.4% (95% CI: 9.0,
87.8) reduction in treatment effect for HAQ in patients with
moderate depression/anxiety at baseline.
No significant interaction was found between extreme
symptoms of depression/anxiety at baseline and HAQ
outcomes and receipt of prednisolone (b coeffi-
cient = 0.19, S.E. = 0.26, standardized mean differ-
ences = 0.04, P= 0.45). However, the effect of steroidal
treatment on HAQ outcomes was 0.48 for patients with-
out depression/anxiety at baseline, decreasing to 0.29
for patients with extreme depression/anxiety. This repre-
sents a 59.7% (95% CI: 0.42, 1.61) reduction in treat-
ment effect for HAQ in patients with extreme depression/
anxiety at baseline, which although reflecting a clinically
meaningful reduction in size of effect, may have failed to
reach statistical significance due to the small proportion of
patients with extreme symptoms at baseline.
No significant interaction between mood status at base-
line and receipt of prednisolone was found for DAS-28
outcomes. Patients with moderate depression/anxiety at
baseline who received prednisolone had somewhat
increased DAS-28 outcomes in comparison with patients
with no depression/anxiety at baseline receiving prednis-
olone (b coefficient = 0.52, S.E. = 0.30, standardized mean
differences = 0.14, P= 0.08). Patients with extreme base-
line depression/anxiety symptoms receiving prednisolone
did not report markedly different DAS28 outcomes at
6 months in comparison with patients with no
depression/anxiety symptoms at baseline receiving pred-
nisolone (b coefficient = 0.06, S.E. = 0.62, standardized
mean differences = 0.01, P= 0.93).
No significant interaction was found between mood
status at baseline and receipt of ciclosporin. Neither patients
with moderate symptoms of depression/anxiety (b coeffi-
cient =0.11, S.E. = 0.13, standardized mean differ-
ences=0.06, P= 0.41) nor extreme depression/anxiety
symptoms (b coefficient =0.09, S.E. = 0.26, standardized
mean differences =0.02, P= 0.74) showed a significant re-
duction in HAQ scores in response to ciclosporin treatment,
in comparison with patients with no symptoms at baseline.
Similarly, neither patients with moderate symptoms of
depression/anxiety (b coefficient =0.15, S.E. = 0.31, stan-
dardized mean differences =0.04, P= 0.64) nor extreme
depression/anxiety symptoms (b coefficient =0.43,
S.E. = 0.64, standardized mean differences =0.05,
P= 0.50) showed a significant reduction in DAS scores in
response to ciclosporin treatment, in comparison with pa-
tients with no symptoms at baseline.
Discussion
Our results suggest that baseline depression/anxiety
status predicts both disease activity and disability
across a 2-year follow-up period, and may reduce re-
sponse to prednisolone treatment. Examination of the
components of the DAS reveal that the subjective elem-
ents of TJC and PGA are those most consistently asso-
ciated with mental health, although strong effect sizes
were found for SJC outcomes in relation to persistent de-
pression/anxiety symptoms. These results support previ-
ous systematic review findings that depression/anxiety
influences long-term disease activity. Rathbun et al.’s
[21] systematic review concludes that longitudinal assess-
ments of the relationships between depression/anxiety
and downstream physical health outcomes are limited
by small sample sizes, poor recruitment strategies, a
lack of control of confounding variables and a lack of in-
formation regarding randomization, measurement blinding
and attrition levels. The strength of this paper is that it
directly addresses these limitations: we had a larger
sample size than all but one of the studies included in
Rathbun et al.’s [21] systematic review, recruited con-
secutively from outpatient clinics from multiple centres
across the UK; we adequately controlled for many poten-
tial confounders, including demographic and clinical vari-
ables; and full information about the randomization
process and attrition levels are available in the original
RCT paper [22]. We were also able to assess the impact
of depression/anxiety on a range of both subjectively and
objectively reported outcomes.
Our results suggest that symptoms of depression/anx-
iety may reduce the body’s ability to respond to gluco-
corticoid treatment. This association was significant for
only one outcome, the HAQ measure of physical disability,
although moderate effect sizes were found for several
other outcomes, including DAS, TJC, PGA and ESR. Our
failure to find this relationship in patients taking ciclosporin
tentatively supports the evidence suggesting that depres-
sion/anxiety may induce a state of glucocorticoid resist-
ance [1417], and reduce response to steroidal treatments
specifically.
More consistent relationships were found between de-
pression/anxiety and subjectively measured components
of the DAS-28: TJC and PGA. However, we found large
and near-significant effect sizes when assessing the rela-
tionship between persistence of depression/anxiety over
time and SJC. The adjustment made for baseline physical
health in the analyses and the time points at which pre-
dictor and outcome variables were measured would imply
the depression/anxiety status preceded the worsened
8 www.rheumatology.oxfordjournals.org
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physical health outcomes; however, we cannot claim the
significant associations reported here to be causal rela-
tionships. Further research using time-lagged analysis or
randomized controlled trials would allow confirmation of
the direction of causality.
The limitations of the current study are as follows. First,
the method of measuring depression/anxiety is subopti-
mal. The EQ-5DTM is a generic measure of quality of life,
and its one-item assessment of depression/anxiety is a far
from ideal method of identifying depression/anxiety status
[24]. Rather, responses to this item may reflect a more
general level of psychological distress, and the overlap
between symptoms of depression and the somatic symp-
toms of RA may result in overestimating the number of
patients with depression/anxiety. Despite this, the propor-
tion of patients indicating a constant state of depression/
anxiety in the current research are similar to prevalence
estimates of depression/anxiety in RA, and the percent-
age of patients reporting extreme depression/anxiety at
baseline are substantially lower than those prevalence es-
timates [1, 3]. Therefore, although not a validated measure
of depression/anxiety in RA, the number of patients iden-
tified via the EQ-5DTM may reflect an underestimation of
the number of patients who would be classified as having
probable depression/anxiety when measured with a more
robust measurement tool, resulting in a reduction in effect
size. Thus, the fact that we still found significant associ-
ations despite this indicates that further research is
needed to replicate these findings using a validated meas-
ure for identifying depression/anxiety symptoms.
An additional concern is the representativeness of the
sample for the wider RA population. People from a low
socioeconomic status (SES) are less likely to participate in
medical research, resulting in research samples that tend
to represent higher SES groups [30]. Low SES is asso-
ciated with increased susceptibility to RA [31] and depres-
sion [32], and with worse disease activity, physical health
and quality of life in RA [33]. Patients’ SES was not mea-
sured as part of this study, making it impossible to estab-
lish the extent to which our results reflect patients from
low SES groups, who are more at risk of experiencing
poor health outcomes in RA. SES was not measured in
the original clinical trial; therefore, we were unable to
examine or control for it in our analysis. Future research
would benefit from taking into account the SES levels pre-
sent in the sample, controlling for this in any analysis, and
attempting to replicate these results in a clinical rather
than research sample.
Conclusion
These findings suggest that both baseline and persistent
symptoms of depression/anxiety predict several subject-
ive and objective rheumatological outcome measures,
after controlling for pertinent demographic and disease
characteristics. These findings have several implications.
First, mental health should be routinely measured in
rheumatological randomized controlled trials (RCTs) and
cohorts. Regardless of direction of causality, the associ-
ation between rheumatological outcomes and depression/
anxiety is strong, particularly for patient-reported out-
comes such as PGA and TJC. Whatever the underlying
mechanisms, we suggest that measuring depression/anx-
iety is an easily collected and significant psychomarker of
rheumatological outcome.
Second, mental health status should be measured both
before commencing treatment and throughout the course
of treatment. There is substantial evidence that depres-
sion/anxiety is highly treatable in patients with co-existing
physical disease [34, 35], and even if treating depression/
anxiety has no impact on rheumatological outcome, we
suggest that given the high frequency of depression/anx-
iety in this context, identification and treatment of depres-
sion/anxiety might well be considered part of routine care,
in line with the NICE guidelines [28].
Third, research is required to determine whether treat-
ing depression/anxiety leads to improved rheumatological
outcome, given that DAS-28 scores are used to make
crucial treatment decisions and the relationships we
report between increased baseline depression/anxiety
and persistent depression/anxiety and increased disease
activity suggest that the detection and management of
depression/anxiety in clinical environments may be ne-
cessary for effective disease management [3]. Such an
approach has been used with success in diabetes and
coronary heart disease [36]. Our results suggest the
need for an RCT examining whether the treatment of de-
pression/anxiety in RA impacts physical health outcomes.
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